IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma

Author(s):
Melief, S.M.; Visser, M.; Burg, S.H. van der (0000-0002-6556-0354); Verdegaal, E.M.E. (0000-0002-4449-8707)
Published
2017
Publication type
Article / Letter to editor
Metastatic melanomaAdoptive cell transferImmunotherapyGMPIDOGalectin-3
Date issued
2017-07-31
Language
English
Is part of
Cancer Immunology, Immunotherapy (2017), Vol. 66, no. 7, p. 913-926
hdl
1887/116273
doi
10.1007/s00262-017-1995-x